Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Trop Med Int Health ; 21(12): 1539-1544, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-27699970

RESUMO

OBJECTIVE: To determine the prevalence of asymptomatic cryptococcal antigen (CRAG) using lateral flow assay (LFA) in hospitalised HIV-infected patients with CD4 counts <200 cells/µl. METHODS: Hospitalised HIV-infected patients were prospectively recruited at Instituto de Infectologia Emilio Ribas, a tertiary referral hospital to HIV-infected patients serving the São Paulo State, Brazil. All patients were >18 years old without prior cryptococcal meningitis, without clinical suspicion of cryptococcal meningitis, regardless of antiretroviral (ART) status, and with CD4 counts <200 cells/µl. Serum CRAG was tested by LFA in all patients, and whole blood CRAG was tested by LFA in positive cases. RESULTS: We enrolled 163 participants of whom 61% were men. The duration of HIV diagnosis was a median of 8 (range, 1-29) years. 26% were antiretroviral (ART)-naïve, and 74% were ART-experienced. The median CD4 cell count was 25 (range, 1-192) cells/µl. Five patients (3.1%; 95%CI, 1.0-7.0%) were asymptomatic CRAG-positive. Positive results cases were cross-verified by performing LFA in whole blood. CONCLUSIONS: 3.1% of HIV-infected inpatients with CD4 <200 cells/µl without symptomatic meningitis had cryptococcal antigenemia in São Paulo, suggesting that routine CRAG screening may be beneficial in similar settings in South America. Our study reveals another targeted population for CRAG screening: hospitalised HIV-infected patients with CD4 <200 cells/µl, regardless of ART status. Whole blood CRAG LFA screening seems to be a simple strategy to prevention of symptomatic meningitis.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Antígenos de Fungos/sangue , Cryptococcus , Infecções por HIV/complicações , Hospitalização , Meningite Criptocócica/epidemiologia , Infecções Oportunistas Relacionadas com a AIDS/diagnóstico , Adulto , Fármacos Anti-HIV/uso terapêutico , Brasil/epidemiologia , Contagem de Linfócito CD4 , Cryptococcus/imunologia , Feminino , Infecções por HIV/tratamento farmacológico , Humanos , Imunoensaio/métodos , Masculino , Meningite Criptocócica/diagnóstico , Pessoa de Meia-Idade , Prevalência
2.
Mycopathologia ; 175(1-2): 107-14, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23076561

RESUMO

Disseminated fusariosis has emerged as a significant, usually fatal infection in immunocompromised hosts despite antifungal treatment. We describe here two patients with acute leukemia who developed disseminated amphotericin-resistant fusariosis, and review of six studies of cases series in the literature. Two Fusarium solani strains were isolated from blood and skin cultures of one patient, and one strain from the blood culture of the second patient. Both patients died despite antifungal treatment. Strains were identified by sequencing of ITS1 and ITS4 regions. Random amplified polymorphic DNA analysis of the three F. solani isolates showed a low degree of similarity. Screening for Fusarium spp. contaminants within our facility was negative. Using the CLSI M-38-A2 broth dilution method and E tests(®), we found that the MICs were low for voriconazole (0.12 and 0.5 mg/L, respectively), unexpectedly high for amphotericin B (≥8 and ≥32 µg/mL, respectively) and itraconazole (≥16 mg/ml). Patients with leukemia or persistent neutropenia should be assessed for disseminated fungal infections, including biopsy and skin cultures. Antifungal susceptibility tests are important due to the possibility of the strains being amphotericin resistant. Treatments must be aggressive, with high doses of antifungals or combined therapy.


Assuntos
Anfotericina B/farmacologia , Antifúngicos/farmacologia , Fusariose/diagnóstico , Fusariose/patologia , Fusarium/efeitos dos fármacos , Leucemia Aguda Bifenotípica/complicações , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Idoso , DNA Fúngico/química , DNA Fúngico/genética , DNA Espaçador Ribossômico/química , DNA Espaçador Ribossômico/genética , Farmacorresistência Fúngica , Evolução Fatal , Fusariose/microbiologia , Fusarium/isolamento & purificação , Humanos , Masculino , Testes de Sensibilidade Microbiana , Análise de Sequência de DNA
3.
Rev Iberoam Micol ; 25(4): 242-5, 2008 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-19071894

RESUMO

We report a clinical case of cerebral infection caused by Cryptococcus gattii in a 10 year-old boy. Clinical and laboratory exams did not demonstrate any apparent immunosuppressed state (HIV antibody and the tuberculin skin tests, both negative, were performed; blood cells count and immunoglobulin levels were within normality). Treatment was begun with amphotericin B-deoxycholate but renal toxicity signs led to its substitution by fluconazole. The infection proceeded even after treatment with fluconazole. In vitro determination of minimum inhibitory concentration values were high for itraconazole (= or > 2 microg/ml), fluconazole and 5-flucytosine (= or > 64 microg/ml) and low for amphotericin B (1.0 microg/ml). Renal toxicity signs, induced by amphotericin B, progression of infection after fluconazole, and likely in vivo resistance to this triazole made this case difficult to treat. In vitro drug interaction tests confirmed probable synergism between amphotericin B and 5-flucytosine (frational inhibitory concentration - FIC = 0.375). In contrast, a probable additive effect was observed for amphotericin B and fluconazole (FIC = 0.75). Initial treatment of persistent high intracranial pressure was insufficient and neurological surgery was necessary. Antifungal susceptibility tests and Cryptococcus species identification were important in selecting appropriate antifungal therapy.


Assuntos
Antifúngicos/farmacologia , Cryptococcus/isolamento & purificação , Meningite Criptocócica/microbiologia , Anfotericina B/farmacologia , Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Criança , Cryptococcus/efeitos dos fármacos , Farmacorresistência Fúngica Múltipla , Sinergismo Farmacológico , Fluconazol/farmacologia , Fluconazol/uso terapêutico , Flucitosina/farmacologia , Humanos , Imunocompetência , Hipertensão Intracraniana/etiologia , Hipertensão Intracraniana/cirurgia , Itraconazol/farmacologia , Masculino , Meningite Criptocócica/diagnóstico , Meningite Criptocócica/tratamento farmacológico , Testes de Sensibilidade Microbiana , Punção Espinal , Derivação Ventriculoperitoneal
4.
Antimicrob Agents Chemother ; 51(4): 1573-6, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17261632

RESUMO

In vitro susceptibility of 58 isolates of Pichia anomala to five antifungal drugs using two broth microdilution methods (CLSI and EUCAST) was analyzed. Low susceptibility to itraconazole was observed. Fluconazole, voriconazole, amphotericin B, and caspofungin showed good antifungal activity, although relatively high drug concentrations were necessary to inhibit the isolates.


Assuntos
Antifúngicos/farmacologia , Infecção Hospitalar/microbiologia , Fungemia/microbiologia , Testes de Sensibilidade Microbiana/métodos , Pichia/efeitos dos fármacos , Anfotericina B/farmacologia , Fluconazol/farmacologia , Fungemia/epidemiologia , Humanos , Itraconazol/farmacologia , Pichia/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...